A phase II efficacy and safety study of HB0025 (a PD-L1/VEGF bispecific antibody) in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer.

Authors: Judong Li, Wei Wei, Ziyi Wang, Xin Zhang, Yuping Sun, Hao Yu, Hongying Yang, Xiumin Li, Li Li, Xiujie Sheng, Jun Gao, Chang Liu, Yuanhuan Xiong, Jinmei Yu, Yi Huang, Li Sun, Zhu Qiao, Xiangyang Zhu, Xiuqiang Ma, Lee Li

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.5602

Source: Full article


Abstract

5602